LY 288513
Modify Date: 2025-08-26 15:32:51
LY 288513 structure
|
Common Name | LY 288513 | ||
|---|---|---|---|---|
| CAS Number | 147523-65-7 | Molecular Weight | 436.30100 | |
| Density | 1.476g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H18BrN3O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LY 288513LY288513, a selective non-peptide CCK-B receptor antagonist with an IC50 value of 16 nM. LY288513 possesses both anxiolytic and antipsychotic potential[1][2][3]. |
| Name | LY 288513,(4S,5R)-N-(4-Bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide |
|---|
| Description | LY288513, a selective non-peptide CCK-B receptor antagonist with an IC50 value of 16 nM. LY288513 possesses both anxiolytic and antipsychotic potential[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 16 nM (CCK-B receptor)[1] |
| In Vitro | LY288513 (10 nM; 2 days) suppresses the effects of CCK-8 on CD4+ T cell subset-specific transcription factors[2]. RT-PCR[2] Cell Line: CD4+ T cells Concentration: 10 nM Incubation Time: 2 days Result: Suppressed the effects of CCK-8 on CD4+ T cell subset-specific transcription factors. |
| In Vivo | LY288513 (3, 10 mg/kg, i.p.; 10, 30 mg/kg, p.o.) produces an anxiolytic-like action[3]. LY288513 (1000 mg/kg, p.o.) potentiates the effects of a CNS depressant, slightly lowered body temperature, and had modest sedative effects only at the highest dose examined[3]. Animal Model: Male CD-l mice[3] Dosage: 3, 10 mg/kg; 10, 30 mg/kg Administration: I.p.; p.o. Result: Displayed anxiolytic-like effects in the elevated plusmaze. |
| References |
| Density | 1.476g/cm3 |
|---|---|
| Molecular Formula | C22H18BrN3O2 |
| Molecular Weight | 436.30100 |
| Exact Mass | 435.05800 |
| PSA | 61.44000 |
| LogP | 5.19260 |
| Index of Refraction | 1.676 |